Rain Oncology Q2 EPS $(0.61) Misses $(0.51) Estimate
Portfolio Pulse from Benzinga Newsdesk
Rain Oncology reported Q2 losses of $(0.61) per share, missing the analyst consensus estimate of $(0.51) by 19.61%. This is a 7.58% increase over losses of $(0.66) per share from the same period last year.
August 10, 2023 | 8:33 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Rain Oncology's Q2 earnings missed analyst estimates by 19.61%, but showed a 7.58% improvement from last year.
Rain Oncology's Q2 earnings missed the analyst consensus estimate, which could negatively impact investor sentiment and potentially lead to a short-term drop in the stock price. However, the year-over-year improvement might mitigate some of this negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100